Page 95 - Read Online

Page 421 Gutierrez et al. Cancer Drug Resist 2021;4:414-23 I http://dx.doi.org/10.20517/cdr.2020.113

Financial support and sponsorship
This work was supported by California Tobacco-Related Disease Research Program Grant: Combined
genotoxic effects of alternative tobacco products and alcohol use (No. 28IR-0050, TRO) and Irell & Manella
Graduate School of Biological Sciences: Payson and Chu Fellowship.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer 2012;12:104-
20.
2. Ahmad A, Nay SL, O’Connor TR. Direct Reversal Repair in Mammalian Cells. In: Clark Chen, editor. Advances in DNA Repair. Rijeka,
Croatia: InTech; 2015. p. 95-128.
3. Kondo N, Takahashi A, Ono K, Ohnishi T. DNA damage induced by alkylating agents and repair pathways. J Nucleic Acids
2010;2010:543531.
4. Tano K, Shiota S, Collier J, Foote RS, Mitra S. Isolation and structural characterization of a cDNA clone encoding the human DNA repair
protein for O6-alkylguanine. Proc Natl Acad Sci U S A 1990;87:686-90.
5. Hayakawa H, Koike G, Sekiguchi M. Expression and cloning of complementary DNA for a human enzyme that repairs O6-methylguanine
in DNA. J Mol Biol 1990;213:739-47.
6. Xu-Welliver M, Pegg AE. Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase.
Carcinogenesis 2002;23:823-30.
7. Lindahl T, Demple B, Robins P. Suicide inactivation of the E. coli O6-methylguanine-DNA methyltransferase. EMBO J 1982;1:1359-63.
8. Warren JJ, Forsberg LJ, Beese LS. The structural basis for the mutagenicity of O(6)-methyl-guanine lesions. Proc Natl Acad Sci U S A
2006;103:19701-6.
9. Costello JF, Futscher BW, Kroes RA, Pieper RO. Methylation-related chromatin structure is associated with exclusion of transcription
factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines. Mol Cell Biol
1994;14:6515-21.
10. Costello JF, Futscher BW, Tano K, Graunke DM, Pieper RO. Graded methylation in the promoter and body of the O6-methylguanine
DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem 1994;269:17228-37.
11. Harris LC, Remack JS, Brent TP. In vitro methylation of the human O6-methylguanine-DNA methyltransferase promoter reduces
transcription. Biochim Biophys Acta 1994;1217:141-6.
12. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by
promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000;60:2368-71.
13. Qi Z, Tan H. Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a
systematic review and meta-analysis. Biosci Rep 2020;40:BSR20194127.
14. Mitra S, Kaina B. Regulation of repair of alkylation damage in mammalian genomes. Prog Nucleic Acid Res Mol Biol 1993;44:109-42.
15. Christmann M, Verbeek B, Roos WP, Kaina B. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors:
enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta 2011;1816:179-90.
16. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med
2005;352:997-1003.
17. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based
therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-45.
18. Boeckmann L, Nickel AC, Kuschal C, et al. Temozolomide chemoresistance heterogeneity in melanoma with different treatment
regimens: DNA damage accumulation contribution. Melanoma Res 2011;21:206-16.
19. Cen L, Carlson BL, Pokorny JL, et al. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft
models. Neuro Oncol 2013;15:735-46.
20. Fan CH, Liu WL, Cao H, Wen C, Chen L, Jiang G. O6-methylguanine DNA methyltransferase as a promising target for the treatment of